SCHEMBL4573407

SCHEMBL4573407

Cc1ccc(NS(=O)(=O)c2ccc(C(N)=O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.74
MAPT P10636 1/20 0.74
ALDH1A1 P00352 4/20 0.65
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
LMNA P02545 2/20 0.65
ALOX12 P18054 1/20 0.65
BRD4 O60885 1/20 0.64
GFER P55789 1/20 0.63
HDAC3 O15379 1/20 0.62
HDAC4 P56524 1/20 0.62
HDAC1 Q13547 1/20 0.62
HDAC7 Q8WUI4 1/20 0.62
HDAC2 Q92769 1/20 0.62
HDAC10 Q969S8 1/20 0.62
HDAC11 Q96DB2 1/20 0.62
HDAC8 Q9BY41 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
HDAC9 Q9UKV0 1/20 0.62
HDAC5 Q9UQL6 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318007 1.00 HPGD (0.74) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL28170795 0.87 MAPT (0.79) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL1030477 0.85 GFER (0.83) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL12338982 0.85 MAPT (1.00) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL3767094 0.85 MAPT (1.00) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL2005010 0.84 CA12 (0.81) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL3086762 0.84 CA1 (0.66) MAPTALDH1A1MEN1KMT2ABRD4
SCHEMBL7211675 0.84 MAPT (0.74) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL3081178 0.83 MEN1 (0.65) HPGDMAPTALDH1A1MEN1KMT2A
SCHEMBL5452240 0.83 TMPRSS6 (0.73) ALDH1A1MEN1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207632-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-08-28 US disclosed
WO-2008055233-A1 PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207632-A1 PROTEIN KINASE INHIBITORS ERBB3, ERBB2, AXL HPGD 4263/4885MAPT 1472/4885ALDH1A1 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.